Zinc phenolsulfonate
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Zinc phenolsulfonate is an ingredient in ophthalmic solutions indicated in the treatment of minor irritation and conjunctivitis.
- Generic Name
- Zinc phenolsulfonate
- DrugBank Accession Number
- DB15793
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
- Weight
- Average: 411.7
Monoisotopic: 409.910852 - Chemical Formula
- C12H10O8S2Zn
- Synonyms
- p-hydroxybenzenesulfonic acid zinc salt
- Phenozin
- Zinc p-phenolsulfonate
- Zinc p-phenolsulphonate
- Zinc paraphenolsulfonate
- Zinc paraphenolsulphonate
- Zinc phenolsulfonate
- Zinc phenolsulphonate
- Zinc sulfocarbolate
- External IDs
- Caswell No. 921A
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Conjunctivitis Combination Product in combination with: Naphazoline (DB06711), Sulfacetamide (DB00634), Lidocaine (DB00281) ••• ••• •••••••• • ••••• Used in combination to treat Eye redness Combination Product in combination with: Naphazoline (DB06711) •••••••••••• Used in combination to treat Foreign body sensation in eye Combination Product in combination with: Naphazoline (DB06711) •••••••••••• Used in combination to treat Heavy feeling of the eyelid Combination Product in combination with: Naphazoline (DB06711) •••••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Diaret Tab Zinc phenolsulfonate (30 mg / tab) + Aluminum hydroxide (70 mg / tab) + Attapulgite (350 mg / tab) + Pectin (45 mg / tab) Tablet Oral Produits Francais Labs Inc. 1981-12-31 1997-05-30 Canada Diarex Tab Zinc phenolsulfonate (30 mg / tab) + Aluminum hydroxide (70 mg / tab) + Attapulgite (350 mg / tab) + Pectin (45 mg / tab) Tablet Oral Nutribon (1986) Inc. 1995-12-31 1996-09-30 Canada Racord Two 7 Zinc phenolsulfonate (.4 mg / 2.54 cm) + Racepinephrine hydrochloride (.225 mg / 2.54 cm) Packing Dental Pascal International Corporation 1992-12-31 1998-07-23 Canada Racord Two No 10 Zinc phenolsulfonate (1.45 mg / 2.5 cm) + Racepinephrine hydrochloride (.3 mg / 2.5 cm) Packing Dental Pascal International Corporation 1996-08-14 1998-07-23 Canada Racord Two No 8 Zinc phenolsulfonate (.4 mg / 2.5 cm) + Racepinephrine hydrochloride (.23 mg / 2.5 cm) Packing Dental Pascal International Corporation 1997-08-12 1998-07-23 Canada
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 4O71YT5YB5
- CAS number
- 127-82-2
- InChI Key
- ZNVKGUVDRSSWHV-UHFFFAOYSA-L
- InChI
- InChI=1S/2C6H6O4S.Zn/c2*7-5-1-3-6(4-2-5)11(8,9)10;/h2*1-4,7H,(H,8,9,10);/q;;+2/p-2
- IUPAC Name
- zinc(2+) bis(4-hydroxybenzene-1-sulfonate)
- SMILES
- [Zn++].OC1=CC=C(C=C1)S([O-])(=O)=O.OC1=CC=C(C=C1)S([O-])(=O)=O
References
- General References
- AIFA approved drug products: Oftalmil (Naphazoline / Zinc phenolsulfonate) ophthalmic solution [Link]
- External Links
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution / drops Ophthalmic Tablet Oral Packing Dental - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.272 mg/mL ALOGPS logP 1.35 ALOGPS logP 0.85 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) -2.6 Chemaxon pKa (Strongest Basic) -6.1 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 77.43 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 37.54 m3·mol-1 Chemaxon Polarizability 14.87 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at August 28, 2020 15:42 / Updated at May 14, 2021 01:08